Related Experiment Video

Updated: Mar 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy

Zhengming Xiong1, Elisabet Ampudia-Mesias1, Rob Shaver1

  • 1University of Minnesota, Pediatrics, Division of Hematology and Oncology, Minneapolis, MN 55455, USA.

Immunotherapy
|August 4, 2016
PubMed

Insights

Blocking CD200, a checkpoint molecule, can enhance the immune system's response to tumor-derived vaccines. This approach may improve cancer immunotherapy efficacy, particularly for brain tumors like glioblastoma.

Area of Science:

  • Immunology
  • Oncology
  • Neuro-oncology

Background:

  • Over 400 clinical trials are investigating tumor-derived vaccines for cancer treatment.
  • Glioblastoma and other brain tumors show variable responses to current vaccine therapies.
  • CD200 acts as a checkpoint blockade, inducing immune tolerance and hindering anti-tumor responses.

Purpose of the Study:

  • To investigate the role of CD200 in suppressing immune responses to tumor-derived vaccines.
  • To evaluate the efficacy of a CD200 peptide inhibitor in overcoming immune tolerance.

Main Methods:

  • Tumor-derived vaccines were administered to assess immune responses.
  • A CD200 peptide inhibitor was used to activate antigen-presenting cells.
  • Leukocyte infiltration, cytokine/chemokine production, and cytolytic activity were measured.

Main Results:

  • Glioma-derived CD200 was found to suppress anti-tumor immune responses following vaccination.
  • The CD200 peptide inhibitor successfully overcame immune tolerance.
  • Inhibition of CD200 significantly increased immune cell infiltration, cytokine/chemokine levels, and cytolytic activity.

Conclusions:

  • CD200 suppresses the immune system's response to cancer vaccines.
  • Blocking CD200 can enhance the efficacy of tumor-derived vaccines.
  • Targeting CD200 represents a promising strategy for improving cancer immunotherapy outcomes, especially for brain tumors.
Keywords:
CD200 proteincheckpoint blockadeimmunotherapy

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.8K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K